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This paper is an overview of vaccine antigens against malaria produced in plants. Plant-based expression systems represent an
interesting production platform due to their reduced manufacturing costs and high scalability. At present, diﬀerent Plasmodium
antigens and expression strategies have been optimized in plants. Furthermore, malaria antigens are one of the few examples of
eukaryotic proteins with vaccine value expressed in plants, making plant-derived malaria antigens an interesting model to analyze.
Up to now, malaria antigen expression in plants has allowed the complete synthesis of these vaccine antigens, which have been able
to induce an active immune response in mice. Therefore, plant production platforms oﬀer wonderful prospects for improving the
access to malaria vaccines.
1.Introduction
Malaria is a major global health problem caused by para-
sites of the genus Plasmodium. This disease is responsible
for the death of over one million people annually, and
approximately three billon people are at risk of infection by
bothPlasmodiumfalciparumandPlasmodiumvivaxparasites
[1, 2]. About 90% of the disease burden occurs in the most
poverty-stricken sub-Saharan African countries. However,
countries of Asia, Latin America, Middle East, and Europe
are also aﬀected [3]. Among the species of Plasmodium
known to cause disease in humans: P. falciparum and P. vivax
have received special attention for vaccine development. P.
falciparum is responsible for most malaria-induced deaths
and has therefore been the focus of the greater part of
research [4]. On the other hand, P. vivax is often the most
prevalent malaria infection in tropical and subtropical areas
[5, 6].
Vaccination against malaria is considered the most
eﬃcient method to prevent this infectious disease [7].
However, although several vaccines are under development,
ac o m p l e t e l ye ﬀective vaccine against malaria is not yet
available. In particular, RTS,S, a potential vaccine targeting
the preerythrocytic stage of the parasite, has shown the
most promising results so far [8]. However, this vaccine
is not fully eﬀective, and thus more eﬃcacious, second-
generation vaccines are needed. In this sense, good progress
is being made in the development of potential vaccines
directed to the asexual blood and sexual stages of the parasite
[9, 10]. In the ﬁrst case, vaccines are designed either to
stop invasion of erythrocytes or to kill intraerythrocytic
parasites [8]. In the second case, vaccines aim to prevent
mosquitoes from becoming infected by preventing parasite
fertilization and/or by inhibiting early development in the
insect vector. This is referred to as transmission-blocking
(TB) immunity and is mediated by speciﬁc antibodies and
other factors ingested during the blood meal, which inhibit
parasite development in the mosquito [11, 12]. These anti-
bodies recognize proteins expressed on either gametocytesor
parasite stages that develop in the mosquito midgut and are
considered to be potential malaria vaccine candidates [13].
This interruption of parasite transmission from patients
to mosquitoes provides the basis for the feasibility of TB
vaccines (TBV) of stopping transmission from infected to
noninfected people [10]. These ﬁndings have stimulated
research into the human immune mechanisms involved in2 Journal of Biomedicine and Biotechnology
protection against infection and disease [14, 15] and into
the blockage of parasite transmission from the host to the
mosquito [13, 16].
Most of the vaccines available today belong to one of
three categories: attenuated microbes, a killed version of
the original pathogen, or protein subunits [17]. Each of
them has its own associated advantages and disadvantages
in terms of safety, immunogenicity, and general feasibility
in terms of the ability to develop in to a commercial
product. The disadvantages of live, attenuated vaccines in
primates and humans include their side eﬀects and risks for
breakthrough infection. In contrast, recombinant subunit
vaccine approaches oﬀer one of the safest alternatives [18,
19].
Since a malaria vaccine based on attenuated parasites is
not feasible in humans, several antigens from malaria para-
sites are being expressed in diﬀerent heterologous expression
systems like bacteria, yeast, insects, and mammalian cells
[2, 8, 20–23]. However, the high costs estimated for a
successful immunization strategy and scalable methods for
vaccine production, distribution and delivery, together with
the lack of infrastructure in malaria-endemic areas, are the
main challenges in the development of a subunit malaria
vaccine[20].Inthiscontext,thecapacityoftransgenicplants
to produce properly folded proteins at low costs makes them
attractive expression systems [24, 25].
Plant-based expression systems represent an interesting
production platform due to their reduced manufacturing
costs and high scalability. In addition, plants have the ability
to generate complex recombinant proteins with desired
structures, maintaining biological functions and oﬀering
greater safety because plants do not harbor mammalian
pathogens or microbial toxins [22, 26–29]. However, plant-
expression systems have been poorly explored for develop-
ment of vaccines against human parasite pathogens. In fact,
only few antigens from Plasmodium ssp. and Toxoplasma
gondii have been expressed in plants [25, 30–39]. At present,
whereas T. gondii antigen expression in plants is just begin-
ning, diﬀerent Plasmodium antigens and expression strate-
gies have been optimized in plants. Furthermore, malaria
antigens are one of the few examples of eukaryotic proteins
with vaccine value expressed in plants, making plant-derived
malaria antigens an interesting model to analyze. For this
reason, this paper is an overview of vaccine antigens against
malaria produced in plants.
2. Plant-Made Vaccines
In the last twenty years, plants have been used as bioreactors
for the biosynthesis of products with biotechnological inter-
est, such as subunit vaccines [40, 41]. An increasing number
of antigens derived from either viruses or bacteria have been
expressed using transgenic and transient expression in whole
plants or plant cell cultures [42]. Among them, mucosal
vaccines for diarrheal diseases, hepatitis B and rabies, as
well as injectable vaccines for non-Hodgkin’s lymphoma,
H1N1 and H5N1 strains of inﬂuenza A virus, and Newcastle
disease have been assayed [43]. Many of these antigens
have demonstrated eﬃcacy and safety in animal models
and preclinical studies [42]. In fact, Dow AgroSciences [44]
obtained the ﬁrst commercial plant-made vaccine approved
for Newcastle illness in chicken. This vaccine was developed
and puriﬁed from tobacco cell cultures [44].
In addition to their use as bioreactors, plants can be used
as potential delivery systems for oral vaccines [43]. In partic-
ular, plant tissues provide protection and prevent degrada-
tion of the antigen when it passes through the gut [45, 46].
It has been demonstrated that plant-made vaccines applied
to mucosal surfaces in the absence of adjuvant are able to
induce a protective immune response, suggesting that some
phytochemicals could synergistically aﬀect the immuno-
genicity of plant-expressed antigens acting as endogenous
adjuvants [47–53]. In addition, plants are known for their
natural immune-stimulating or antimicrobial activity due
to secondary metabolites as lectins, saponins, alkaloids,
phenolic compounds, and ﬂavonoids [54]. Moreover, some
commonly occurring plant components, such as unmethy-
lated CpGs motifs of DNA, carotenoids and immunogenic
proteins, have adjuvant properties [55, 56]. Hence, it might
be assumed that plants can be used in the short term as
oral or injectable vaccine producers and as a source of
endogenous adjuvants as well.
3. Plant-Made Antigens againstthe Asexual
BloodStageofPlasmodium
A small number of merozoite surface proteins have been
analyzed as vaccines against the asexual bloodstage of Plas-
modium by inducing an immune response that either blocks
invasion of erythrocytes or inhibits its subsequent mul-
tiplication [57–59]. Apical membrane antigen-1 (AMA1),
merozoitesurfaceprotein-1 (MSP1),anderythrocytesurface
antigens are under clinical trials [11, 60–64]. Some of them
have been expressed in plants, and their immunogenicity
assayed (Table 1)[ 25, 33, 35, 36, 39, 65].
The 19-kDa C-terminal fragment of P. falciparum mero-
zoite surface protein 1 (PfMSP119) was the ﬁrst malaria
antigen expressed in plants by stable transformation, with
a very low expression level (∼0.0035% of the total soluble
protein (TSP)) [30]. Afterwards, a plant-codon-optimized
version of the 42kDa C-terminal fragment of PfMSP1
(PfMSP142) was designed and synthesized, and expressed in
transgenic Arabidopsis thaliana seeds [35]. Also, for protein-
stable accumulation, the plant-optimized PfMSP142 gene
wasfusedtothephaseolinpeptidesignal[66]ortothelysine-
rich protein [35]. These strategies resulted in a substantial
improvement of PfMSP142 expression (approximately 5% of
TSP) [35].
Plant codon optimization has also been implemented to
improve the expression level of Plasmodium yoelii merozoite
surface protein 4/5 (PyMSP4/5) [25], another important
vaccine candidate with high eﬀectiveness in protecting
mice against a lethal challenge [67, 68]. In this case, this
optimized PyMSP4/5 version was expressed in transgenic
tobacco plants and its expression level was six-fold higher
than that obtained with the native protein [25]. In general,Journal of Biomedicine and Biotechnology 3
Table 1: Malaria vaccine antigens expressed in plants.
Malaria antigens Plant/expression system Expression level Functional evaluation Refs.
Asexual blood stage antigens
P. falciparum MSP119 (PfMSP119) Tobacco/nuclear
transformation 0.0035% TSP Not reported [30]
P. falciparum MSP142 (PfMSP142) A. thaliana seeds/nuclear
transformation 5% TSP Immunoreactivity to sera from
malaria-infected patients [35]
P. yoelii MSP4/5 (PyMSP4/5)
Tobacco/nuclear
transformation
Tobacco/magnICON
0.02–0.04% TSP
10% TSP (1-2mg/g FW)
Immunogenic by i.p. and oral delivery to
mice
Induction of speciﬁc antibodies by oral
delivery or primed by a DNA vaccine to
mice
[25]
[33]
P. yoelii MSP119 (PyMSP119) Tobacco/magnICON 23% TSP (3-4mg/g FW)
Immunogenic by i.p. delivery with
Freund’s adjuvant or oral administration
without any adjuvant
[65]
P. falciparum AMA1 (PfAMA1)
Tobacco/chloroplast
transformation
Lettuce/chloroplast
transformation
13.1% TPS
7.3% TSP
Induction of speciﬁc antibodies in s.c.
and orally immunized mice
Immunoreactivity to native parasite
proteins
[36]
P. falciparum MSP1 (PfMSP1)
Tobacco/chloroplast
transformation
Lettuce/chloroplast
transformation
10.1% TSP
6.1% TSP
Induction of speciﬁc antibodies in s.c.
and orally immunized mice
Immunoreactivity to native parasite
proteins
[36]
P. vivax MSP1 (PvMSP1) B. napus/nuclear
transformation Not reported
Induction of antigen-speciﬁc IgG1 and
increase in Th1-related cytokines IL-12
(p40), TNF, and IFN-γ in orally
immunized mice
[39]
P. vivax CSP (PvCSP) B. napus/nuclear
transformation Not reported
Induction of antigen-speciﬁc IgG1 and
increase in Th1-related cytokines IL-12
(p40), TNF, and IFN-γ in orally
immunized mice
[39]
Sexual stage antigens
P. falciparum P230 (Pfs230) Tobacco/agroinﬁltration 800mg/kg FW
Induction of transmission-blocking
antibodies in s.c. and i.m. immunized
mice Immunoreactivity to native parasite
proteins
[38]
P. falciparum P25 (Pfs25) Tobacco/agroinﬁltration 0.25 and 0.4mg/g FW
Induction of transmission-blocking
antibodies in i.m. immunized mice
Immunoreactivity to native parasite
proteins
[37]
TSP: total soluble protein. FW: fresh weight. i.p.: intraperitoneal. i.s.: intrasubcutaneous. i.m.: intramuscular.
rare codons, AU-rich destabilizing sequences and putative
polyadenylation and splicing signals may contribute to rapid
mRNA decay, thus limiting the expression of foreign genes
in plants. In the plant codon-optimized PyMSP4/5 antigen,
the A+T content is reduced from 67% to 53%, and the
AT-rich regions are disrupted, allowing the reduced A+T
gene version to be more eﬃcient in antigen production
than the native version [25]. Codon optimization has also
been implemented in protozoan parasite T. gondii antigens
expressed in plants [31]. In this last case, the A+T content
(54%) in the optimized T. gondii SAG1 version is increased,
negatively aﬀecting SAG1 expression [31]. These results,
together with the results obtained in Plasmodium,s u p p o r t
the idea that a high A+T content is correlated with a low
protein expression.
More recently, Webster et al. [33] have expressed the
plant codon-optimized PyMSP4/5 in Nicotiana benthamiana
leaves, using the deconstructed tobacco mosaic virus-based
transientexpressionsystem,magnICON,fromICONGenet-
ics (Germany) [69] and found expression levels of up to 10%
TSP(∼1-2mg/goffreshweight)[33].TheuseofmagnICON
has also been found to increase the expression level of the
plant codon-optimized P. yoelii MSP119 (PyMSP119)t oa t
least 23% TSP (∼3-4mg/g of fresh weight) [65]. All together,
these results show that not only codon optimization but also
the viral provector system improves the expression level of
plant-made malaria antigens [33, 65]. Indeed, plant codon
optimization combined with the magnICON expression
system has been shown to allow an increase of up to 100 fold
with respect to the transgenic tobacco system [25, 33].4 Journal of Biomedicine and Biotechnology
Studies on the immunogenicity of these plant-made
malaria antigens have shown that PyMSP4 and PyMSP119
expressed in plants are able to elicit an immune response
by intraperitoneal (i.p.) or oral vaccination in a murine
model [25, 33, 36, 39, 65]. These ﬁndings provide a rationale
for the development of a plant-made oral vaccine against
malaria. The report by Wang et al. [25] was the ﬁrst to
demonstratetheimmunogenicpropertiesofPyMSP4/5.First
they found that oral immunization with E. coli-produced
PyMSP4/5 in the presence of the cholera toxin B subunit
of Vibrio cholera (CTB) induced a signiﬁcant increase in the
systemic-speciﬁcantibodiesandapartialprotectionagainsta
lethal challenge with P. yoelii [24]. Then, they found that oral
immunization of mice using plant-made malaria antigens
elicited an eﬀective immunity against this parasite [25].
They demonstrated that oral immunization using plant-
made malaria antigens elicited an eﬀective immunity against
this parasite [25]. However, immunization with plant-made
antigens elicited a lower immune response than E. coli-made
antigen immunization. Thus, Webster et al. [33] proposed
increasing the antigen dose using the magnICON system
[33]. This strategy allowed them to increase the antigen dose
orally administered. However, a higher antigen dose (leaf
powder containing 100μg of PyMSP4/5) was not enough to
induce a protective response against P. yoelli [33].
Thus, they hypothesized that the presence of dimeric
antigen forms produced in E. coli enhances its immuno-
genicity, while the presence of monomeric forms in the
plant-made antigen would explain its inability to induce
protection. Similar results were obtained by Ma et al. [65]:
although the plant-made PyMSP119 was immunogenic when
delivered i.p. with Freund’s adjuvant or orally without
any adjuvant, the speciﬁc antibody titers were lower than
those induced with the same dose as that of E. coli-made
antigens [65]. Like that observed in PyMSP4/5, the higher
proportion of dimers and multimers contained in E. coli-
made PyMSP119 suggests that the multimers are more stable
and immunogenic [65]. In case that this hypothesis is
demonstrated,furtherinnovations willbe requiredtoinduce
a protective immunity.
Finally, P. falciparum apical membrane antigen-1
(PfAMA1) and PfMSP1, both fused to CTB, have been
expressed in transplastomic plants [36]. This strategy
allowed accumulating CTB-PfAMA1 and CTB-PfMSP1
fusion proteins up to 13.1% and 10.1% of TSP in tobacco
plants. In addition, since the expression of antigenic
proteins in tobacco plants is not suitable for oral delivery in
humans, Davoodi-Semiromi et al. [36] expressed these same
chimeric proteins in lettuce chloroplasts and found that the
expression levels of these malaria antigens fused to CTB
in lettuce were up to 7.3% and 6.1% of TSP, suﬃcient for
oral delivery evaluation [36, 39]. These authors combined
two attractive strategies to improve the level of expression:
plastid expression and chimeric protein production. While
many chloroplasts in each cell and multiple copies of the
plastid genome per cell make the high level of protein
expression possible [20, 23], the carrier proteins contribute
to a higher stability of the target protein in plants [43]. The
levels of dual cholera-malaria vaccine antigens were ∼50 fold
higher in tobacco and ∼30fold higher in lettuce than other
malaria antigens expressed in tobacco transgenic lines [36].
On the other hand, the lettuce chloroplast transformation
opens the possibility of producing a green vaccine that could
be orally administered without cold chain requirements.
Indeed, Davoodi-Semiromi et al. [36] also found that
subcutaneous and oral vaccination with candidate PfAMA1
and PfMSP1 genes fused to CTB are highly immunogenic
in mice. Moreover, they also showed a signiﬁcant parasitic
inhibition, providing evidence that the antibodies generated
from immunized mice are eﬀective in preventing parasite
invasion of red blood cells [36].
Several reports have assessed plant production of
chimeric proteins as potential vaccines [36, 43]. The
expression of chimeric proteins carrying epitopes from
diﬀerent pathogens, linkers, or adjuvant sequences would
allow increasing the immunogenicity of the recombinant
antigen [43]. In addition, a great number of models have
demonstrated the feasibility to elicit broad cellular and
humoral immune responses using such a type of molecules
[43]. In particular, Davoodi-Semiromi et al. [36]d e m o n -
strated that CTB-PfAMA1 and CTB-PfMSP1 are able to
elicit a humoral response by mucosal routes. However,
they did not evaluate the cellular immune response. In
addition, it is necessary to identify new, safe, and nontoxic
adjuvants, particularly for those capable of strongly boosting
cellular immune responses. In this context, leaves have a
large number of heat shock proteins (HSPs), which have
been demonstrated to have adjuvant properties in other
organisms [70, 71]. Indeed, plants expressing HSP90 are
able to induce in vitro B-cell proliferation from na¨ ıve mice,
suggesting that these proteins could be excellent carriers of
interesting vaccine antigens and peptides expressed in plants
[72].
Other edible plant species has been explored to produce
malaria antigens [39]. Brassica napus has been used to
express P. vivax MSP1 (PvMSP1) and the P. vivax circum-
sporozoite protein (PvCSP), and to synthesize a chimeric
recombinant gene containing PvMSP-1, a Pro-Gly linker
motif, and PvCSP [39]. Oral immunization of mice with
plant-made MLC chimeric recombinant protein successfully
induced antigen-speciﬁc IgG1 production [39]. Additionally,
theTh1-relatedcytokinesIL-12,TNF,andIFN-γ weresignif-
icantly increased in the spleens of BALB/c mice, supporting
the idea that oral vaccines could be developed based on
the use of food plant platforms for the production and
deliveryofvaccineantigens,contributingtoasubstantialcost
reduction [22].
4. Plant-Made Antigens againstSexual
BloodStageofPlasmodium
As mentioned above, an alternative strategy to develop
an eﬃcient malaria vaccine is to obtain vaccines directed
against proteins found in the sexual stages of P. falciparum
parasites present in the Anopheles mosquito midgut, known
as transmission-blocking vaccines (TBVs). A positive aspect
of this type of TBV is that they attack the parasite atJournal of Biomedicine and Biotechnology 5
avulnerablestageofitslifecycle,whenithastotransferfrom
one host to another and when its numbers are very small
[73]. Clinical trials have been conducted with vaccines based
on the ookinete antigens of P. falciparum and P. vivax with
induction of TB antibodies [10, 74].
Farrance et al. [38] used the transient N. benthamiana
expression system to express the P.falciparumgametesurface
antigen P230 (Pfs230) (Table 1). They demonstrated that
antibodies against this protein block the progression of the
parasite’s life cycle in the mosquito and thus block the
transmission to the human host [8, 75]. Pfs230 is present
on the surface of P. falciparum gametocytes and gametes
and is expressed during human infection [8, 75]. The N-
terminal region of Pfs230 spanning aminoacids 444 to
730 was fused to the ER retention sequence (KDEL) and
produced using plant-based transient-expression system by
agroinﬁltration[38].Therecombinantproteinwasexpressed
in approximately 800mg/kg in whole fresh leaf tissue,
being 100% soluble [38]. This plant-made Pfs230 elicited
high titers of anti-Pfs230 antibodies when administered to
rabbits in the presence of complete/incomplete Freund’s
adjuvant. Furthermore, the antibodies generated combined
with this adjuvant were shown to bind speciﬁcally to
the native protein in P. falciparum on the surface of
gametes/zygotes, resulting in signiﬁcant TB activity (TBA)
[38].
Farrance et al. [37] also expressed an ookinete antigen
present in the sexual form of the parasite—Pfs25—using the
transientN.benthamianaexpressionsystem(Table 1).Pf25is
able to induce TB antibodies and is present in the zygote and
ookinete stages but is not expressed during human infection
[8]. In order to evaluate the role of the Lichenase molecule
(LicKM) as a carrier [54] and the eﬀects of N-glycosylation
onthegenerationofafunctionalimmuneresponse,Farrance
etal.[37] obtained four constructscarrying the recombinant
Pfs25 protein for transient expression in plants. Indepen-
dently of the protein versions evaluated, Pfs25 expression
levelswerebetween0.25and0.4mg/goffreshleaftissue[37].
Also, these authors observed that this recombinant protein
with N-glycans had the lowest titers, while the Pfs25 lacking
glycans (Pfs25-LG) showed the highest IgG titers in mice
immunized intramuscularly (i.m.). However, the fusion to
LicKM elicited a higher titer than that of the Pfs25 lacking
glycans alone. The authors concluded that nonglycosylated
antigens generated high antibody titers and enhanced TBA.
In addition, they were able to eliminate the negative eﬀect
of the presence of glycans on the Pfs25 protein’s ability
to induce a functional immune response when Pfs25 was
fused to LicKM [38]. Glycosylation of some antigens can
aﬀect their immunogenicity [37]. According to this, the
plant-produced nonglycosylated and glycosylated versions
determined that the nonglycosylated antigens generated
higher antibodies titers and enhanced TBA [37]. Since
glycosylation does not occur in chloroplasts and the natural
pathogen organism (Plasmodium) does not glycosylate the
target proteins, these results support the idea that the
chloroplast would be the best compartment to express this
group of proteins, where the glycosylation may aﬀect their
antigenicity.
Conclusion
Development of an eﬀective malaria vaccine has been a
great challenge for medical science. Up to now, malaria
antigen expression in plants has allowed the complete
synthesis of these vaccine antigens, which have been able to
induce an active immune response in mice. Therefore, plant
production platforms oﬀer wonderful prospects for improv-
ing the access to malaria vaccines. Indeed, plant-derived
multiantigen malaria vaccines could be formulated through
mixingtransgenicplantmaterialsorpolycistronicoperonsin
chloroplasts expressing several malaria antigens. In addition,
eﬃcient malaria antigen expression in the lettuce chloroplast
for oral immunization is a signiﬁcant advancement that
allows the oral delivery of subunit vaccines combined with
a potent mucosal adjuvant. However, the local immune
response induced by plant-made malaria antigens has not
been analyzed yet. Indeed, most of these published reports
are centered in the systemic humoral response. In this sense,
further research is needed to understand the mucosal and
systemic cellular immune response elicited by plant-made
malaria antigens orally delivered.
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